April 2019 - Global Life Science Business Partnering - News & Updates
Highlights of April 2019
- Cipla to pick up 30% stake in African connected healthcare firm Brandmed.
- Zydus Cadila inks pact with Italy's SIFI to market intraocular lenses in India.
- Ipca Labs to buy API maker Ramdev Chemical for US$15.5 Million in a cash deal aimed at growing its active pharmaceutical ingredients (API) business.
- Cipla signs US$22 Million pact with Pulmatrix Inc for new asthma drug.
- Vanta Bioscience signs US$4.18 Million deal with Emcure Pharma.
- Bain-Piramal fund to invest US$144 Million in Panacea Biotec.
- Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to US$135 Million
- Shanghai Miracogen taps Synaffix's antibody-drug conjugate tech in a deal worth up to US$125 Million.
- Lilly taps Avidity's antibody-oligonucleotide conjugate tech in US$35 Million deal.
- Therillia Development Co has acquired Tavec Pharmaceuticals, the leading therapeutic exosome company.
- BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®.
- ReNeuron Partners with Fosun Pharma in China.
Updates at Aagami:
- Aagami to attend BIO International Convention 2019 in June (Philadelphia) and also represent multiple clients. Meeting calendar open.
- MyBioGate partners with Aagami for China Focus@BIO Philadelphia (June 2, 2019 at Loews Philadelphia Hotel)
- The forum features premier 1-to-1 networking opportunities prior to and during the forum, which is bringing together 100+ investors and pharma leaders from China and healthcare innovators. It is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.
- To Register, please click below: https://events.mybiogate.com/bio/general-registration/